Viral polymerase inhibitors

摘要

An isomer, enantiomer, diastereoisomer, or tautomer of a compound represented by formula (II) is disclosed to be used in the treatment or prevention of hepatitis C virus (HCV) infection. A is 0, S, or NR1 wherein R1 is selected from H or C1-6 alkyl optionally substituted; R2 is selected from: H, halogen, R21, OR21, SR21, C00R21, SO2N(R22)2, N(R22)2, CON(R22)2 NR22C(O)R22 or NR22C(O)NR22; B is CR3 wherein R3 is selected from (C3-7)cycloalkyl, (C6-10)bicycloalkyl, (C6-10)bicylcoalkenyl, napthyl and Het, each being optionally substituted with from 1 to 4 substituents; K is N or CR4 wherein R4 is H, halogen, (C1-6)alkyl, haloalkyl, (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl; or R4 is OR41 or SR41 or COR41; L is N or CR5 wherein R5 has the same definition as R4 defined above; M is N or CR7 wherein R7 has the same definition as R4 defined above; Y1 is O or S; Z is OR6 or NR9R10.